Diana Horta

Dr. Diana Horta

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AVAlbert Villoria
Albert Villoria
VGVíctor García
Víctor García
ADAngelina Dosal
Angelina Dosal
LMLaura Moreno
Laura Moreno
AMAntònia Montserrat
Antònia Montserrat
MRMaría José Ramírez-Lázaro
María José Ramírez-Lázaro
Fatigue is a common and bothersome symptom in inflammatory bowel disease (IBD) patients. The study was aimed to determine the relationship of biological and psychological factors with IBD-related fatigue. Consecutive clinically inactive IBD outpatients receiving immunosuppressants or biological drugs were enrolled between January and December 2013. Patients completed a Fatigue score (FACIT-F), various psychological, quality of life (IBDQ-9), and IBD activity scores. Biological parameters were assessed, including levels of interleukins (IL-5, IL-8 and IL-12) and micronutrients. We prospectively recruited 202 patients (28% ulcerative colitis and 72% Crohn’s disease) for the study. Fatigue measured by FACIT-F score was prevalent in the studied population (54%, 96/177) and higher than in the general population. In the univariate analysis no relation was found between IL levels or micronutrient deficiencies and fatigue. Fatigue was significantly related to female sex, Crohn’s disease, joint disorders, body mass index (BMI), psychological tests, thiopurine use, and anti-TNF treatment. All these variables were included in the multivariate analysis. Female sex (OR: 4.8), high BMI (OR:1.2) and higher depression rates (OR:1.2) were predictors of increased fatigue. High IBDQ-9 score (OR: 0.82) was significantly related to lower degrees of fatigue. Fatigue was prevalent in quiescent IBD patients with moderate-to-severe disease. It was associated with high levels of depression, low quality of life, and female sex. No association was found with the other biological and psychological factors evaluated.

3 January 2023 in Hepatology
Verified
Journal Article
Closed access
ÁDÁlvaro Díaz-González
Álvaro Díaz-González
MHManuel Hernández-Guerra
Manuel Hernández-Guerra
IPIndhira Pérez-Medrano
Indhira Pérez-Medrano
VSVictor Sapena
Victor Sapena
MRMar Riveiro-Barciela
Mar Riveiro-Barciela
CRColHai Registry
ColHai Registry
Background and Aims: In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options. Approach and Results: This was a retrospective, multicenter study of 105 naive AIH patients treated with budesonide as the first-line drug. The control group included 276 patients treated with prednisone. Efficacy was assessed using logistic regression and validated using inverse probability of treatment weighting propensity score. The median time to biochemical response (BR) was 3.1 months in patients treated with budesonide and 4.9 months in those with prednisone. The BR rate was significantly higher in patients treated with prednisone (87% vs. 49% of patients with budesonide, p < 0.001). The probability of achieving BR, assessed using the inverse probability of treatment weighting propensity score, was significantly lower in the budesonide group (OR = 0.20; 95% CI: 0.11–0.38) at any time during follow-up, and at 6 (OR = 0.51; 95% CI: 0.29–0.89) and 12 months after starting treatment (0.41; 95% CI: 0.23–0.73). In patients with transaminases <2 × upper limit of normal, BR was similar in both treatment groups. Prednisone treatment was significantly associated with a higher risk of adverse events (24.2% vs. 15.9%, p = 0.047). Conclusions: In the real-life setting, the use of budesonide as first-line treatment is low, and it is generally prescribed to patients with perceived less disease activity. Budesonide was inferior to prednisone as a first-line drug but was associated with fewer side effects.

18 February 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
AAAlba Ardevol
Alba Ardevol
GIGemma Ibáñez-Sanz
Gemma Ibáñez-Sanz
JPJoaquim Profitos
Joaquim Profitos
CACarles Aracil
Carles Aracil
JCJosep M. Castellvi
Josep M. Castellvi
CVCandid Villanueva
Candid Villanueva

1 December 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
LLLaura-Patricia Llovet
Laura-Patricia Llovet
DHDiana Horta
Diana Horta
MEMaria García Eliz
Maria García Eliz
MBMarina Berenguer
Marina Berenguer
EFEmilio Fábrega
Emilio Fábrega
MLMaria Carlota Londono
Maria Carlota Londono

15 May 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
DHDiana Horta
Diana Horta
ALAlba Lira
Alba Lira
MSMeritxell Sanchez-Lloansi
Meritxell Sanchez-Lloansi
AVAlbert Villoria
Albert Villoria
MTMarcelo Teggiachi
Marcelo Teggiachi
XCXavier Calvet
Xavier Calvet
Fatigue is a common symptom in patients with inflammatory bowel disease (IBD), and it often persists despite clinical remission. Acupuncture has been shown to be effective for treating fatigue in patients with many chronic diseases. The main objective of the study was to assess the efficacy of electroacupuncture (EAc), compared with sham EAc (ShEAc) or being on a waitlist (WL), for treating fatigue in patients with quiescent IBD in a single-blind randomized trial. Fifty-two patients with IBD in clinical remission and fatigue were randomly assigned to 1 of 3 groups: EAc, ShEAc, or WL. Patients in the EAc and ShEAc groups received 9 sessions over 8 weeks. Fatigue was evaluated with the IBD-validated Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-FS). Baseline characteristics were similar in the 3 groups. Both EAc and ShEAc presented improved Functional Assessment of Chronic Illness Therapy-Fatigue Scale scores compared with baseline: the respective improvements were 9.53 (95% confidence intervals, 6.75–12.3, P < 0.001) and 5.46 points (95% confidence intervals, 2.7–9.7, P = 0.015), respectively. No significant changes were observed in the WL group. In the comparison of treatment groups, EAc was nonsignificantly better than ShEAc (EAc, 33.27 and ShEAc, 28.13, P = 0.168); both EAc and ShEAc improved fatigue scores significantly compared to WL (24.5; P = 0.01 and 0.04, respectively). Both EAc and ShEAc reduced fatigue scores in IBD patients when compared to WL. No differences were observed between EAc and ShEAc, although the study was not powered to rule out a difference. Acupuncture may offer improvements to patients with few other treatment alternatives. Clinical Trials Org Id: NCT02733276.

15 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
PRPABLO RUIZ-RAMÍREZ
PABLO RUIZ-RAMÍREZ
GPGerard Carreras Pierres
Gerard Carreras Pierres
IFIngrid Fajardo
Ingrid Fajardo
ETEva Tristán
Eva Tristán
ACAnna Carrasco
Anna Carrasco
MEMaria Esteve
Maria Esteve
Introduction: The study of intraepithelial lymphocytes (IEL) by flow cytometry is a useful tool in the diagnosis of coeliac disease (CD). Previous data showed that an increase in %TCRγδ+ and decrease of %CD3− IEL constitute a typical CD cytometric pattern with a specificity of 100%. However, there are no data regarding whether there are differences in the %TCRγδ+ related to sex, age, titers of serology, and degree of histological lesion. Study aims: To confirm the high diagnostic accuracy of the coeliac cytometric patterns. To determine if there are differences between sex, age, serology titers, and histological lesion grade. Results: We selected all patients who fulfilled “4 of 5” rule for CD diagnosis (n = 169). There were no differences in %TCRγδ+ between sexes (p = 0.909), age groups (p = 0.986), serology titers (p = 0.53) and histological lesion grades (p = 0.41). The diagnostic accuracy of complete CD cytometric pattern was: specificity 100%, sensitivity 82%, PPV 100%, NPV 47%. Conclusion: We confirmed, in a validation cohort, the high diagnostic accuracy of complete CD pattern irrespective of sex, age, serology titers, and grade of mucosal lesion.